Which Country Is Blincyto (Blinatumomab) Cheapest In? — 2026 Guide

Why does the price differ so much between countries?

Blincyto (blinatumomab) is a 35 microgram lyophilised vial reconstituted for continuous intravenous infusion delivered over several days via an ambulatory pump, used to treat B-cell precursor acute lymphoblastic leukaemia. Unlike a single-dose injection or a fortnightly infusion, Blincyto's dosing regimen requires the first one to two cycles to be administered with the patient hospitalised, so that clinicians can monitor for cytokine release syndrome and neurotoxicity in real time before any ambulatory continuation is considered safe. That administration model means Blincyto's effective "price" to a health system includes days of inpatient bed occupancy, specialist nursing and monitoring infrastructure that a simple list-price comparison never captures, and it also means the drug simply cannot be supplied anywhere without that hospital infrastructure in place — a constraint that shapes access far more than any pricing mechanism does.

In Türkiye, the Ministry of Health anchors the reference price to the lowest ex-factory price found in a designated basket of EU member states, then converts it using the "pharmaceutical euro" (Dönemsel Avro Değeri) — fixed at 65% of the previous year's average Central Bank euro rate rather than the live spot rate. That mechanism, published via the TİTCK price list and gazetted in the Resmî Gazete, is a major reason Turkish list prices for oncology biologics sit structurally below free-pricing markets — but for Blincyto specifically, the price paid is only meaningful in the context of a hospital capable of delivering weeks of monitored continuous infusion.

Germany evaluates Blincyto's benefit under its AMNOG framework, where a manufacturer sets a free price for the first six months of a new indication before a negotiated price applies, backdated to month seven. The United Kingdom's NICE ordinarily applies a cost-per-QALY threshold that was raised from the long-standing £20,000–£30,000 band to £25,000–£35,000, announced 1 December 2025 and effective from April 2026 (see NICE); for a relapsed or refractory leukaemia indication with a genuinely orphan-sized patient population, NICE may instead route some evaluations through its Highly Specialised Technologies programme, which applies a more permissive cost-effectiveness framework recognising the smaller evidence base achievable in ultra-rare or narrowly defined populations.

The United States has no equivalent government reference mechanism for a drug like Blincyto: pricing is largely free at launch and negotiated privately between the manufacturer, hospitals and payers, with the continuous-infusion delivery model meaning acquisition happens almost exclusively through specialist cancer centres rather than retail or even standard hospital pharmacy channels. For the underlying mechanics of why Türkiye's published prices sit where they do, see our explainer on why medicines cost less in Türkiye.

How is the price set in each country?

The table below compares pricing systems, not prices. Each country publishes — or does not publish — its own official list, and that published list is the only figure worth relying on. Follow the link in the last column and read the current entry yourself.

How can I obtain a medicine legally from a lower-price market?

There is a lawful route in most countries, and it starts in the same place everywhere: a valid prescription in your own name, issued by the physician treating you. What differs is the import permit. The procedures below are stated only where they could be verified at the national authority.

United Arab Emirates. MOHAP operates a permit to import medicines for personal use through its Electronic Drug Establishment service. The permit is free and is issued within 3 working days. You log in with a MOHAP account or UAE Pass.

Saudi Arabia. Applications run through the SFDA Controlled Drugs System at cds.sfda.gov.sa, under a guideline published on 14 August 2025. Read the current SFDA regulations page before you travel — the requirements are revised periodically.

Qatar. For non-controlled medicines there is no pre-approval: you may carry up to a 60-day supply through the Green Channel, in the original packaging, with a copy of the prescription and a signed, stamped letter from your doctor. For controlled medicines you need advance approval and must use the Red Channel; supporting documents must be no older than 6 months and in Arabic or English.

Kuwait and Azerbaijan. Confirm the current procedure directly with the national authority before shipping or travelling — Kuwait Ministry of Health and Azerbaijan Tariff Council. We do not publish a step list for these two countries because the procedure could not be verified at source.

1. United Arab Emirates — obtain a prescription in the applicant's own name, issued within the last 3 months.
2. Obtain a medical report from the treating facility, authenticated by the health authority and issued within the last year.
3. Prepare an Emirates ID or passport copy for the applicant.
4. Log in to the MOHAP service with a MOHAP account or UAE Pass and submit the personal-import application.
5. Keep the quantity within the limit: no more than a 1-month supply for controlled medicines, and no more than a 3-month supply for non-controlled medicines.
6. Wait for the decision — the service is free and normally issued within 3 working days.
7. Contact MOHAP on 800 111 11 or at import.export@mohap.gov.ae if the application stalls.

What is named patient supply?

Named patient supply is the international concept behind almost every lawful cross-border medicine route. The clearest codified example is the United Kingdom's MHRA Guidance Note 14, built on Regulation 167 of the Human Medicines Regulations 2012.

Four conditions define it: the order must be unsolicited; the product must be specified by the prescriber; the prescriber must be directly responsible for the patient; and there must be a genuine special clinical need that no authorised product meets.

The honesty point matters here: the European Court has held that "financial considerations cannot, in themselves" establish a special clinical need. A lower price in another country is not, by itself, a lawful basis for a named-patient import. The lawful bases are clinical.

Is the Blincyto I'm being offered genuine?

No falsified batches of Blincyto have been recorded in WHO's alert series to date. That is a genuinely reassuring fact about this specific product's track record, but it is not a reason to relax verification, and in Blincyto's case the administration model itself is one of the strongest practical safeguards: because the drug can only be given via continuous infusion in a hospital equipped to manage cytokine release syndrome and neurotoxicity, there is effectively no legitimate route to self-administer it or receive it outside a specialist oncology unit.

That same administration model means anyone offered Blincyto outside a hospital oncology setting — for home delivery, personal import, or through an unaffiliated pharmacy — should treat the offer as inherently implausible rather than merely risky. A genuine Blincyto course cannot exist outside the hospital infrastructure that makes it safe to give in the first place.

• Scan the carton's GS1 DataMatrix and confirm it decodes to AI 01 (GTIN), AI 21 (serial number), AI 17 (expiry) and AI 10 (batch) — a code that will not scan, or scans to the wrong product, is a hard stop.
• If the vial is sourced in Türkiye, check that its karekod is notified to the national İlaç Takip Sistemi (İTS) track-and-trace system at its.saglik.gov.tr before it leaves the pharmacy.
• Ask for a continuous 2–8°C temperature log covering the actual shipment received by the hospital pharmacy, not a generic cold-chain certificate — Blincyto must never be frozen or shaken.
• Confirm reconstitution and pump preparation take place only in a licensed hospital pharmacy under oncology supervision, never pre-mixed and delivered.
• No falsified batches of Blincyto have been logged in WHO's alert series to date; cross-check any concern against our WHO falsified medicine alerts tracker rather than assuming the absence of a listing means informal sourcing is safe.
• Treat any offer of Blincyto for home use, self-administration or personal import as implausible by design — its continuous-infusion, hospital-monitored delivery model has no legitimate outpatient equivalent.
• Review the full verification workflow in our guide to checking that a medicine is genuine.

Frequently asked questions

Sources

• Resmî Gazete — Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar No. 11031 — retrieved: 2026-07-28
• TİTCK — published medicine price list — retrieved: 2026-07-28
• MOHAP (UAE) — import medicine for personal use — retrieved: 2026-07-28
• SFDA (Saudi Arabia) — regulations — retrieved: 2026-07-28
• SFDA Controlled Drugs System — retrieved: 2026-07-28
• Qatar MOPH — drug prices — retrieved: 2026-07-28
• Kuwait Ministry of Health — retrieved: 2026-07-28
• Azerbaijan Tariff Council (Tarif Şurası) — retrieved: 2026-07-28
• NICE (United Kingdom) — retrieved: 2026-07-28
• G-BA (Germany) — AMNOG benefit assessment — retrieved: 2026-07-28
• RAND — International prescription drug price comparisons (published 1 Feb 2024) — retrieved: 2026-07-28
• Frontiers in Pharmacology — European hospital price transparency study (9 Mar 2026) — retrieved: 2026-07-28
• MHRA Guidance Note 14 — supply of unlicensed medicinal products — retrieved: 2026-07-28

Country availability pages for this medicine

Related pages

Haematology infusions

Related high-cost medicines